Tesofensine has followed an unusual path through pharmaceutical research. It was not originally created as a weight-loss medication. Instead, researchers first investigated it as a possible treatment for neurological disorders, particularly Parkinson’s disease and Alzheimer’s disease. When trials failed to demonstrate sufficient neurological benefits, an unexpected observation redirected the drug’s development: some participants taking tesofensine lost a meaningful amount of weight.
That observation transformed tesofensine from a largely unsuccessful neurological candidate into an experimental obesity treatment. It also illustrates an important part of drug development. A medicine may fail in its original indication but still produce a biological effect that becomes valuable in another area of medicine.
Today, tesofensine remains an investigational drug rather than a routinely approved obesity medication. It has produced encouraging weight-loss results in clinical studies, but questions about cardiovascular effects, long-term safety, regulatory approval, and its place among newer obesity treatments remain unresolved.
The inception of tesofensine
Tesofensine, previously identified by the development code NS-2330, originated at the Danish biotechnology company NeuroSearch. The compound belongs to a class of drugs known as monoamine reuptake inhibitors.
Monoamines are chemical messengers used by the nervous system. Tesofensine inhibits the reuptake of three of them: noradrenaline, also called norepinephrine; dopamine; and serotonin. Blocking reuptake leaves more of these neurotransmitters available between nerve cells and can alter processes such as attention, motivation, movement, appetite, and reward-seeking behavior.
This mechanism initially made tesofensine interesting to researchers studying neurodegenerative diseases. Dopamine has a particularly important role in movement, and the loss of dopamine-producing neurons is a defining feature of Parkinson’s disease. Researchers therefore hoped that modifying dopamine signaling—along with serotonin and noradrenaline signaling—might improve Parkinson’s symptoms.
Tesofensine was also studied in Alzheimer’s disease. The reasoning was broader in this case: increasing monoamine activity might improve alertness, cognition, motivation, or other behavioral symptoms associated with neurological decline.
The compound entered clinical development during the late 1990s and early 2000s. However, enthusiasm for its neurological potential declined after controlled trials failed to demonstrate a convincing clinical benefit.
What happened in the Parkinson’s disease studies?
One important study evaluated tesofensine as a stand-alone treatment in 261 people with early Parkinson’s disease. Participants received placebo or one of three daily tesofensine doses—0.25, 0.5, or 1 milligram—for 14 weeks.
Researchers measured changes using the Unified Parkinson’s Disease Rating Scale. Although the 1-milligram group showed a statistically significant advantage at week six, that difference was not maintained through the end of the study. Overall, none of the tested doses produced a significantly greater improvement than placebo at week 14.
The investigators concluded that tesofensine did not provide sufficient benefit for early Parkinson’s disease at the doses studied. They also noted several common adverse effects, including insomnia, constipation, and dry mouth. Elevated heart rate and decreased body weight occurred more frequently at the highest dose.
The lack of neurological effectiveness was disappointing, but the repeated weight loss was difficult to ignore. Researchers found similar patterns when reviewing participants from Alzheimer’s and Parkinson’s trials. People receiving tesofensine tended to lose more weight than those receiving placebo, with larger effects generally appearing at higher doses.
That observation changed the direction of the program. Instead of asking whether tesofensine could improve neurological symptoms, researchers began asking whether it could intentionally reduce appetite and body weight.
The transition into obesity research
The possibility of repurposing tesofensine emerged at a time when obesity medicine had relatively limited pharmaceutical options. Many older appetite suppressants produced only modest weight loss, and some had been withdrawn because of cardiovascular or psychiatric safety problems.
Because tesofensine influenced serotonin, dopamine, and noradrenaline simultaneously, researchers believed it might affect several components of eating behavior:
Noradrenaline could increase satiety and sympathetic nervous system activity.
Dopamine could alter food motivation and reward-seeking behavior.
Serotonin could contribute to fullness and appetite regulation.
The drug’s long half-life also made once-daily administration possible. However, its central nervous system activity and noradrenergic effects meant that cardiovascular and psychiatric safety would require close attention.
A dedicated Phase II trial, known as TIPO-1, was launched to investigate tesofensine in adults with obesity. The registered study recruited people with a body mass index between 30 and 40 and compared several tesofensine doses with placebo. Participants also received dietary guidance and were expected to follow a calorie-restricted diet.
The influential Phase II obesity trial
The best-known tesofensine obesity study was a 24-week randomized, double-blind, placebo-controlled trial conducted at five obesity-management centers in Denmark. It enrolled 203 adults and compared placebo with daily tesofensine doses of 0.25, 0.5, and 1 milligram.
The study reported dose-related weight loss. Before adjustments for participants who discontinued treatment, average weight reductions were approximately:
2.0% with placebo
4.5% with 0.25 milligrams of tesofensine
9.2% with 0.5 milligrams
10.6% with 1 milligram
In another statistical analysis accounting for missing data, the reported reductions were approximately 2.2%, 6.7%, 11.3%, and 12.8%, respectively.
The findings suggested that tesofensine could produce considerably more weight loss than the obesity drugs available when the study was conducted. The researchers also reported improvements in some metabolic measurements, including triglycerides, total cholesterol, insulin, and glycated hemoglobin.
However, the results came with important cautions. Adverse effects included dry mouth, constipation, nausea, insomnia, and increased heart rate. The highest dose produced the strongest weight-loss effect but also raised the greatest tolerability concerns.
The study’s publication later received an expression of concern from The Lancet. An expression of concern is not the same as a formal retraction, and it does not automatically establish that every reported result is invalid. Nevertheless, it is an important part of the scientific record and should be disclosed whenever the study is discussed. The trial’s ClinicalTrials.gov record links both the original paper and the subsequent expression of concern.
For that reason, the Phase II results should be interpreted as promising but not conclusive. Independent replication, transparent reporting, larger studies, and longer follow-up are necessary before a drug can be considered an established treatment.
How tesofensine may reduce body weight
Tesofensine is commonly described as a triple monoamine reuptake inhibitor. By inhibiting the transporters that normally remove noradrenaline, dopamine, and serotonin from the space between neurons, it increases or prolongs signaling through these neurotransmitter systems.
Its apparent effect on body weight seems to come primarily from reduced energy intake rather than a dramatic increase in energy expenditure. In practical terms, participants may feel less hungry, become satisfied after eating less food, or experience less desire to continue eating.
A controlled study examining appetite sensations found that tesofensine increased feelings of fullness and reduced prospective food consumption. Animal studies have also suggested that noradrenergic and dopaminergic pathways contribute to the reduction in food intake.
More recent laboratory research has examined tesofensine’s effects on the lateral hypothalamus, a brain region involved in feeding behavior, arousal, and energy regulation. These experiments suggest that its mechanism may be more complicated than simply “raising three neurotransmitters.” Altered activity within particular hypothalamic circuits could help explain how the drug suppresses feeding.
Laboratory findings, however, are not equivalent to proof of long-term benefit in patients. A mechanism can be scientifically plausible while the final balance of effectiveness and safety remains uncertain.
Cardiovascular and other safety considerations
Tesofensine’s influence on noradrenaline is both part of its potential effectiveness and one of its main safety concerns. Increased noradrenergic activity can raise heart rate and, in some patients, blood pressure.
Clinical-development documents reported increases in heart rate of up to approximately eight beats per minute, as well as smaller increases in blood pressure at doses between 0.25 and 1 milligram per day. The size and clinical importance of these changes may differ between patients, but even modest cardiovascular effects matter when a medication is intended for long-term use.
This issue is particularly relevant because many people with obesity already have hypertension, diabetes, sleep apnea, or cardiovascular disease. A successful obesity medication must therefore do more than lower weight during a short study. It must demonstrate that its benefits outweigh its risks across a broad patient population and over an appropriate treatment period.
Other reported adverse effects have included insomnia, dry mouth, constipation, dizziness, headache, nausea, reduced appetite, and changes in energy or attention. Anxiety has also been reported in studies involving the combination product discussed below.
Tesofensine should not be treated like an ordinary dietary supplement. Products sold online as “research chemicals” may be unregulated, incorrectly labeled, contaminated, or supplied at unreliable concentrations. Purchasing such products does not provide the safeguards of a legitimate clinical trial, regulated pharmacy, or physician-supervised treatment.
Tesomet: combining tesofensine with metoprolol
Researchers have also developed Tesomet, a fixed-dose combination of tesofensine and metoprolol. Metoprolol is a beta-1 selective blocker commonly used for cardiovascular conditions. Its purpose in Tesomet is to reduce increases in heart rate and blood pressure associated with tesofensine while preserving the appetite-suppressing effect.
Tesomet has been studied for hypothalamic obesity, a rare and difficult-to-treat condition that can occur after tumors, surgery, radiation, or other injuries affecting the hypothalamus. People with hypothalamic obesity can experience rapid weight gain, intense hunger, lower energy expenditure, and poor responses to conventional lifestyle treatment.
In a small Phase II randomized study, 21 adults with hypothalamic obesity received either Tesomet—0.5 milligrams of tesofensine with 50 milligrams of metoprolol—or placebo for 24 weeks. Eighteen participants completed the blinded treatment period.
The study reported that the Tesomet group lost approximately 7.84 kilograms on average, compared with 0.34 kilograms in the placebo group. The placebo-adjusted difference in percentage weight loss was approximately 6.3%. Researchers did not identify a significant difference in heart rate or blood pressure between the two groups during the study.
These findings were encouraging, but the study was very small. One participant experienced a serious worsening of pre-existing anxiety that investigators considered related to Tesomet, and other frequently reported effects included sleep disturbance, dry mouth, dizziness, and headache. The researchers themselves emphasized the need for larger studies.
Saniona subsequently began a Phase IIb Tesomet program. According to the company, that program was voluntarily paused because of funding limitations rather than a new safety or efficacy finding. Tesomet therefore also remains experimental.
Ownership and later commercial development
NeuroSearch eventually transferred tesofensine-related rights to Saniona in 2014. Saniona later partnered with the Mexican pharmaceutical company Productos Medix for development and potential commercialization in Mexico and Argentina.
Medix completed a Phase III study of tesofensine in adults with obesity and submitted a marketing application to Mexico’s health-products regulator, COFEPRIS. Saniona reported that a COFEPRIS technical committee issued a favorable, but non-binding, opinion in 2023.
The regulatory process did not immediately produce final approval. According to Saniona’s 2025 annual report, Medix revised its submission in response to COFEPRIS feedback and resubmitted the application on February 20, 2025. Saniona’s current investor information describes that marketing-authorization application as under review.
This is an important distinction. Completing a Phase III trial, submitting an application, or receiving a favorable technical opinion does not by itself mean that a medicine has received final marketing authorization.
What is tesofensine today?
As of the latest publicly available company and registry information, tesofensine is best described as an investigational anti-obesity drug with a marketing application under regulatory review in Mexico. It is not an FDA-approved obesity medication in the United States. Its appearance in the FDA’s substance-identification database should not be interpreted as approval; the FDA database specifically notes that assigning a Unique Ingredient Identifier does not imply regulatory review or authorization.
Tesofensine now occupies two related development paths:
Tesofensine alone is being pursued as a possible treatment for general obesity, particularly through the Medix program in Mexico.
Tesofensine combined with metoprolol, under the name Tesomet, has been investigated for rare forms of obesity such as hypothalamic obesity.
Its position in obesity medicine has also changed since the original Phase II study. Modern GLP-1 and dual-incretin medicines have set much higher standards for weight loss and have accumulated large cardiovascular and safety datasets. Any future tesofensine program would need to establish not only that the drug causes weight loss but also that its overall benefit-risk profile is competitive with contemporary options.
The broader significance of tesofensine
Tesofensine’s history demonstrates how scientific development can change direction. A compound created for neurodegenerative disease failed to produce the intended neurological benefits, yet observations from those unsuccessful trials revealed a different and potentially valuable effect.
That does not make tesofensine a proven obesity treatment. Its early studies produced notable weight loss, but the evidence base includes short trials, limited participant numbers, cardiovascular concerns, an expression of concern attached to its most influential publication, and unresolved regulatory questions.
The fairest description is therefore neither that tesofensine is a miracle drug nor that it is a failed experiment. It is a repurposed pharmaceutical candidate with an interesting mechanism, meaningful clinical signals, and substantial questions that still need to be answered.
Until regulators complete their reviews and larger, well-controlled studies establish long-term safety and effectiveness, tesofensine should be discussed as an investigational medicine—not as an approved or independently verified weight-loss product.
Medical disclaimer: This article is for educational purposes and does not provide medical advice. Tesofensine and Tesomet are investigational products in many jurisdictions. No one should purchase, dose, or use an unapproved tesofensine product without appropriate medical and regulatory oversight.
References
Hauser RA, Salin L, Juhel N, Konyago VL. “Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson’s disease.” Movement Disorders. 2007. PubMed record.
Astrup A, et al. “Weight Loss Produced by Tesofensine in Patients With Parkinson’s or Alzheimer’s Disease.” Obesity. 2008. Journal article.
Astrup A, et al. “Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients.” The Lancet. 2008. Study citation and abstract.
National Library of Medicine. “Effect of Tesofensine on Weight Reduction in Patients With Obesity,” NCT00394667. The record also links the 2013 expression of concern. ClinicalTrials.gov record.
Gilbert JA, et al. “The effect of tesofensine on appetite sensations.” Obesity. 2012. PubMed record.
Huynh K, et al. “Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.” European Journal of Endocrinology. 2022. Full text.
National Library of Medicine. “48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol,” NCT03845075. ClinicalTrials.gov record.
Saniona. “Tesomet.” Current development summary and program status. Company pipeline page.
Saniona. “Tesofensine.” Development and regulatory summary. Company pipeline page.
Saniona. Annual Report 2025. Includes information concerning Medix’s February 2025 resubmission to COFEPRIS. Annual report.
U.S. Food and Drug Administration Global Substance Registration System. “Tesofensine.” The record states that UNII availability does not imply regulatory review or approval. FDA substance record.
Bello EP, et al. “Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.” Full-text research article.